Krishgen, as a budding manufacturer of immunoassays and antibodies in India, has been invited by the Indian Government to be a part of their Make-In-India endeavour – NBRIC.

The Department of Biotechnology (DBT) in India has launched a National Biomedical Resource Indigenization Consortium (NBRIC) to drive indigenous innovation focused on developing reagents (used in chemical reactions), diagnostics, vaccines and therapeutics for Covid-19 and other infectious diseases.

This prestigious invite comes to Krishgen as a leading player in the Indian market both importing reagents for use in India, and also manufacturing our own for COVID-19 research and diagnostics.

Krishgen has developed its own range of diagnostic tools (Rapid test, ELISA and PCR kit) for COVID-19, as well as the world’s largest range of ELISA for research and development of therapeutics and vaccines. This includes one of the first Neutralizing Antibody detecting immunoassays as well.